Showing results (81-90 of 176) with videos related to
Sort By:
Pageof 18
Hepatology Research : the Official Journal of the Japan Society of Hepatology|October 26, 2024
Time trend of outcomes according to systemic therapy for patients with unresectable hepatocellular carcinoma: A single-institution studyShinsuke Uchikawa, Tomokazu Kawaoka, Serami Murakami, et al.Journal of Hepatology|June 26, 2010
Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patientsHiromi Abe, Hidenori Ochi, Toshiro Maekawa, et al.Cancers|February 27, 2020
Genomic Characterization of Non-Invasive Differentiated-Type Gastric Cancer in the Japanese PopulationKoki Nakamura, Yuji Urabe, Kenichi Kagemoto, et al.Biochemical and Biophysical Research Communications|April 6, 2018
Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized miceYuji Teraoka, Takuro Uchida, Michio Imamura, et al.BMC Gastroenterology|October 26, 2019
Pruritus in patients with chronic liver disease and serum autotaxin levels in patients with primary biliary cholangitisHatsue Fujino, Mio Tanaka, Michio Imamura, et al.The Journal of Infectious Diseases|September 22, 2016
Protease Inhibitor Resistance Remains Even After Mutant Strains Become Undetectable by Deep SequencingHiromi Kan, Michio Imamura, Takuro Uchida, et al.Antimicrobial Agents and Chemotherapy|July 12, 2017
Persistent Loss of Hepatitis B Virus Markers in Serum without Cellular Immunity by Combination of Peginterferon and Entecavir Therapy in Humanized MiceTakuro Uchida, Michio Imamura, C Nelson Hayes, et al.Journal of Medical Virology|March 20, 2013
Circulating microRNA-22 correlates with microRNA-122 and represents viral replication and liver injury in patients with chronic hepatitis BKeiko Arataki, C Nelson Hayes, Sakura Akamatsu, et al.Clinical Journal of Gastroenterology|August 30, 2019
Successful retreatment with 12 weeks of glecaprevir and pibrentasvir for a genotype 2a HCV-infected hemodialysis patient who failed to respond to 8 weeks of prior glecaprevir and pibrentasvir therapyKazuki Ohya, Michio Imamura, Mitsutaka Osawa, et al.Journal of Medical Virology|April 20, 2011
Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1bYoshimasa Hashimoto, Hidenori Ochi, Hiromi Abe, et al.Pageof 18